Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.48 |
| ▸ | MAOB | P27338 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 8/20 | 0.47 |
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31115543 | 1.00 | MAOA (0.48) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL25389100 | 0.96 | MAOA (0.45) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL30571233 | 0.96 | MAOA (0.45) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL29092682 | 0.87 | NPC1 (0.40) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL5621710 | 0.84 | NPC1 (0.45) | NPC1RAB9ATDP1TLR4TLR2 | |
| SCHEMBL5621713 | 0.84 | NPC1 (0.45) | NPC1RAB9ATDP1TLR4TLR2 | |
| SCHEMBL664995 | 0.82 | ALDH1A1 (0.50) | RAB9ASMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL5543437 | 0.82 | MAOA (0.66) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL377842 | 0.81 | MEN1 (0.36) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL3995992 | 0.81 | MAOA (0.48) | MAOAMAOBNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | disclosed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | disclosed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | disclosed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1546099-A4 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-08-02 | — | — | EP | disclosed |
| EP-1644369-A2 | ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| EP-1546099-A2 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| US-20050038016-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2005005395-A2 | ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004004629-A2 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | MAOA 2714/4885MAOB 2738/4885NPC1 2953/4885 |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | MAOA 139/4885MAOB 78/4885NPC1 1231/4885 |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | MAOA 3020/4885MAOB 2998/4885NPC1 2904/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | MAOA 3924/4885MAOB 3438/4885NPC1 1722/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | MAOA 2714/4885MAOB 2738/4885NPC1 2953/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | MAOA 2714/4885MAOB 2738/4885NPC1 2953/4885 |
| US-10131640-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | MAOA 2714/4885MAOB 2738/4885NPC1 2953/4885 |
| US-20050038016-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | MAOA 139/4885MAOB 78/4885NPC1 1231/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | MAOA 3020/4885MAOB 2998/4885NPC1 2904/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | MAOA 3020/4885MAOB 2998/4885NPC1 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.